Xtant Medical Holdings Inc

Xtant Medical maintains a conservative capital structure with $17.05 million in cash and equivalents and $25.43 million in long-term debt, resulting in a debt-to-equity ratio of 0.5 and a current ratio of 2.65. The company generates $12.55 million in operating cash flow and $7.81 million in free cash flow, supporting its liquidity position despite a net cash negative position after subtracting total debt. Profitability metrics show a return on equity of 9.76% and return on assets of 5.28%, which are below the industry median for medical equipment firms. The company's gross margin of 62.9% (calculated from $84.27 million gross profit on $133.93 million revenue) is in line with industry norms, but operating margin of 7.9% (calculated from $10.57 million operating income) lags behind peers. Geographically, Xtant Medical is heavily concentrated in the U.S., with no material revenue disclosed from international markets. The company operates in a single business segment focused on urology and surgical devices, with no diversification across product lines or geographic regions. Revenue growth has been modest, with $133.93 million in the latest period. Analysts project a mean price target of $1.23, implying a 163% upside from the current $0.47 market price. The company's capital expenditure of -$2.38 million suggests asset sales or reduced investment in physical infrastructure. Risk factors include liquidity constraints due to the net cash negative position and limited diversification. The company has low dilution risk, with basic and diluted shares outstanding aligned at 140.07 million. No material dilution adjustments were applied in valuation models. Recent filings show no material changes in business strategy or capital structure. The company's 10-K filing highlights ongoing regulatory compliance challenges in the medical device sector, but no specific near-term risks were identified in the latest disclosures.